Business Description
Olema Pharmaceuticals inc
NAICS : 325412
SIC : 2834
ISIN : US68062P1066
Share Class Description:
OLMA: Ordinary SharesTotal Employee Number:
137Description
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 127.74 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 8.4 | |||||
3-Year EPS without NRI Growth Rate | 10.6 | |||||
3-Year FCF Growth Rate | 6.5 | |||||
3-Year Book Growth Rate | 6.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.49 | |||||
9-Day RSI | 68.87 | |||||
14-Day RSI | 59.88 | |||||
3-1 Month Momentum % | -29.02 | |||||
6-1 Month Momentum % | -57.71 | |||||
12-1 Month Momentum % | 135.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.88 | |||||
Quick Ratio | 10.88 | |||||
Cash Ratio | 10.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.4 | |||||
Shareholder Yield % | -4.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -46.4 | |||||
ROA % | -41.92 | |||||
ROIC % | -943.4 | |||||
3-Year ROIIC % | -478.26 | |||||
ROC (Joel Greenblatt) % | -11794.92 | |||||
ROCE % | -50.24 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.3 | |||||
Price-to-Tangible-Book | 2.3 | |||||
EV-to-EBIT | -2.99 | |||||
EV-to-Forward-EBIT | -2.42 | |||||
EV-to-EBITDA | -2.99 | |||||
EV-to-Forward-Revenue | 32.1 | |||||
EV-to-FCF | -4.05 | |||||
| Price-to-Net-Current-Asset-Value | 2.38 | |||||
| Price-to-Net-Cash | 2.43 | |||||
Earnings Yield (Greenblatt) % | -33.44 | |||||
FCF Yield % | -13.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OLMA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Olema Pharmaceuticals inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.03 | ||
| Beta | 0.1223 | ||
| 3-Year Sharpe Ratio | 0.62 | ||
| 3-Year Sortino Ratio | 2.05 | ||
| Volatility % | 233.98 | ||
| 14-Day RSI | 59.88 | ||
| 14-Day ATR ($) | 0.809039 | ||
| 20-Day SMA ($) | 10.639 | ||
| 12-1 Month Momentum % | 135.46 | ||
| 52-Week Range ($) | 4.37 - 36.2591 | ||
| Shares Outstanding (Mil) | 87.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Olema Pharmaceuticals inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Olema Pharmaceuticals inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 38 days | ||
| General meeting for 2026 | 2026-06-17 08:00 | 9.19 (-6.89%) | ||
| Goldman Sachs 47(th) Annual Global Healthcare Conference | 2026-06-09 15:20 | 9.96 (-4.23%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 08:45 | 10.69 (-14.41%) | ||
| TD Cowen 7(th) Annual Oncology Innovation Summit | 2026-05-26 12:30 | 13.68 (-1.51%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 14.86 (-1.07%) | ||
| Annual report for 2025 | 2026-03-16 | 14.71 (-3.35%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 14.71 (-3.35%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 14:30 | 24.02 (+2.17%) |
Show
Entries
Olema Pharmaceuticals inc Frequently Asked Questions
What is Olema Pharmaceuticals inc(OLMA)'s stock price today?
The current price of OLMA is $12.64. The 52 week high of OLMA is $36.26 and 52 week low is $4.37.
When is next earnings date of Olema Pharmaceuticals inc(OLMA)?
The next earnings date of Olema Pharmaceuticals inc(OLMA) is 2026-08-11 Est..
Does Olema Pharmaceuticals inc(OLMA) pay dividends? If so, how much?
Olema Pharmaceuticals inc(OLMA) does not pay dividend.
Guru Commentaries on NAS:OLMA
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights -- OLMA | 2026-03-09 |
Articles on Olema Pharmaceuticals inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers